Sep 29, 2025 7:15am EDT Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
Sep 03, 2025 9:15am EDT Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 07, 2025 1:08pm EDT Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Aug 06, 2025 9:15am EDT Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Mar 31, 2025 3:45pm EDT Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
